1
|
Ward JL, Wu Y, Harflett C, Onafuye H, Corol D, Lomax C, Macalpine WJ, Cinatl J, Wass MN, Michaelis M, Beale MH. Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy. Sci Rep 2020; 10:6477. [PMID: 32296088 PMCID: PMC7160102 DOI: 10.1038/s41598-020-63349-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Accepted: 03/27/2020] [Indexed: 02/08/2023] Open
Abstract
Willow (Salix spp.) is well known as a source of medicinal compounds, the most famous being salicin, the progenitor of aspirin. Here we describe the isolation, structure determination, and anti-cancer activity of a cyclodimeric salicinoid (miyabeacin) from S. miyabeana and S. dasyclados. We also show that the capability to produce such dimers is a heritable trait and how variation in structures of natural miyabeacin analogues is derived via cross-over Diels-Alder reactions from pools of ortho-quinol precursors. These transient ortho-quinols have a role in the, as yet uncharacterised, biosynthetic pathways around salicortin, the major salicinoid of many willow genotypes.
Collapse
Affiliation(s)
- Jane L Ward
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK.
| | - Yanqi Wu
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK
- Zhejiang University of Technology, 18 Chaowang Road, Hangzhou, P. R. China
| | - Claudia Harflett
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK
| | - Hannah Onafuye
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK
| | - Delia Corol
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK
| | - Charlotte Lomax
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK
| | - William J Macalpine
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK
| | - Jindrich Cinatl
- Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany
| | - Mark N Wass
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK
| | - Martin Michaelis
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK
| | - Michael H Beale
- Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Hertfordshire, AL5 2JQ, UK.
| |
Collapse
|
2
|
Pieper S, Onafuye H, Mulac D, Cinatl J, Wass MN, Michaelis M, Langer K. Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity. Beilstein J Nanotechnol 2019; 10:2062-2072. [PMID: 31728254 PMCID: PMC6839550 DOI: 10.3762/bjnano.10.201] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Accepted: 10/02/2019] [Indexed: 05/30/2023]
Abstract
Background: Nanoparticles are under investigation as carrier systems for anticancer drugs. The expression of efflux transporters such as the ATP-binding cassette (ABC) transporter ABCB1 is an important resistance mechanism in therapy-refractory cancer cells. Drug encapsulation into nanoparticles has been shown to bypass efflux-mediated drug resistance, but there are also conflicting results. To investigate whether easy-to-prepare nanoparticles made of well-tolerated polymers may circumvent transporter-mediated drug efflux, we prepared poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and PEGylated PLGA (PLGA-PEG) nanoparticles loaded with the ABCB1 substrate doxorubicin by solvent displacement and emulsion diffusion approaches and assessed their anticancer efficiency in neuroblastoma cells, including ABCB1-expressing cell lines, in comparison to doxorubicin solution. Results: The resulting nanoparticles covered a size range between 73 and 246 nm. PLGA-PEG nanoparticle preparation by solvent displacement led to the smallest nanoparticles. In PLGA nanoparticles, the drug load could be optimised using solvent displacement at pH 7 reaching 53 µg doxorubicin/mg nanoparticle. These PLGA nanoparticles displayed sustained doxorubicin release kinetics compared to the more burst-like kinetics of the other preparations. In neuroblastoma cells, doxorubicin-loaded PLGA-PEG nanoparticles (presumably due to their small size) and PLGA nanoparticles prepared by solvent displacement at pH 7 (presumably due to their high drug load and superior drug release kinetics) exerted the strongest anticancer effects. However, nanoparticle-encapsulated doxorubicin did not display increased efficacy in ABCB1-expressing cells relative to doxorubicin solution. Conclusion: Doxorubicin-loaded nanoparticles made by different methods from different materials displayed substantial discrepancies in their anticancer activity at the cellular level. Optimised preparation methods resulted in PLGA nanoparticles characterised by increased drug load, controlled drug release, and high anticancer efficacy. The design of drug-loaded nanoparticles with optimised anticancer activity at the cellular level is an important step in the development of improved nanoparticle preparations for anticancer therapy. Further research is required to understand under which circumstances nanoparticles can be used to overcome efflux-mediated resistance in cancer cells.
Collapse
Affiliation(s)
- Sebastian Pieper
- Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstraße 48, 48149 Muenster, Germany
| | - Hannah Onafuye
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Dennis Mulac
- Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstraße 48, 48149 Muenster, Germany
| | - Jindrich Cinatl
- Institute for Medical Virology, University Hospital, Goethe-University, Paul Ehrlich-Straße 40, 60596 Frankfurt am Main, Germany
| | - Mark N Wass
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Martin Michaelis
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Klaus Langer
- Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstraße 48, 48149 Muenster, Germany
| |
Collapse
|
3
|
Onafuye H, Pieper S, Mulac D, Jr. JC, Wass MN, Langer K, Michaelis M. Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. Beilstein J Nanotechnol 2019; 10:1707-1715. [PMID: 31501742 PMCID: PMC6720578 DOI: 10.3762/bjnano.10.166] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 07/29/2019] [Indexed: 05/17/2023]
Abstract
Resistance to systemic drug therapy is a major reason for the failure of anticancer therapies. Here, we tested doxorubicin-loaded human serum albumin (HSA) nanoparticles in the neuroblastoma cell line UKF-NB-3 and its ABCB1-expressing sublines adapted to vincristine (UKF-NB-3rVCR1) and doxorubicin (UKF-NB-3rDOX20). Doxorubicin-loaded nanoparticles displayed increased anticancer activity in UKF-NB-3rVCR1 and UKF-NB-3rDOX20 cells relative to doxorubicin solution, but not in UKF-NB-3 cells. UKF-NB-3rVCR1 cells were re-sensitised by nanoparticle-encapsulated doxorubicin to the level of UKF-NB-3 cells. UKF-NB-3rDOX20 cells displayed a more pronounced resistance phenotype than UKF-NB-3rVCR1 cells and were not re-sensitised by doxorubicin-loaded nanoparticles to the level of parental cells. ABCB1 inhibition using zosuquidar resulted in similar effects like nanoparticle incorporation, indicating that doxorubicin-loaded nanoparticles successfully circumvent ABCB1-mediated drug efflux. The limited re-sensitisation of UKF-NB-3rDOX20 cells to doxorubicin by circumvention of ABCB1-mediated efflux is probably due to the presence of multiple doxorubicin resistance mechanisms. So far, ABCB1 inhibitors have failed in clinical trials probably because systemic ABCB1 inhibition results in a modified body distribution of its many substrates including drugs, xenobiotics, and other molecules. HSA nanoparticles may provide an alternative, more specific way to overcome transporter-mediated resistance.
Collapse
Affiliation(s)
- Hannah Onafuye
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Sebastian Pieper
- Institute of Pharmaceutical Technology and Biopharmacy, University of Münster, Corrensstr. 48, 48149 Münster, Germany
| | - Dennis Mulac
- Institute of Pharmaceutical Technology and Biopharmacy, University of Münster, Corrensstr. 48, 48149 Münster, Germany
| | - Jindrich Cinatl Jr.
- Institute for Medical Virology, University Hospital, Goethe-University, Paul Ehrlich-Straße 40, 60596 Frankfurt am Main, Germany
| | - Mark N Wass
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Klaus Langer
- Institute of Pharmaceutical Technology and Biopharmacy, University of Münster, Corrensstr. 48, 48149 Münster, Germany
| | - Martin Michaelis
- Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| |
Collapse
|